Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma
Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma
Immunization of mice with the idiotype (Id) immunoglobulin from the murine B cell lymphoma, BCL1, before inoculating tumor cells can induce tumor dormancy. In this model, the tumor cells grow for a short period of time and then regress. The mice live for months or years with approximately 1 million tumor cells in their spleens. Some mice relapse due to decreases in the anti-Id antibody titers or the development of mutations in the residual tumor cells which render them refractory to negative signaling by the anti-Id antibody. In this study we determined whether we could eliminate the residual dormant cells by using a DNA vaccine against the Id or by immunomodulation of T-cell subsets in vivo. Our results demonstrate that dormancy can be maintained by further immunizations with either the BCL1 Id protein or DNA vaccine encoding its single-chain Fv fragment. We also found that a cytotoxic T-cell response was not induced by either in vivo administration of vaccine alone or by the vaccine plus interleukin-2. In addition the injection of anti-cytotoxic T-lymphocyte-associate antigen did not prolong dormancy. Finally, the in vivo administration of anti-CD25 to deplete regulatory T cells did not prolong dormancy. Dormancy in this model is dependent primarily upon anti-Id antibodies, our results suggest that other strategies to target residual dormant BCL1 cells are warranted. They also suggest that the elimination of dormant tumor may represent a greater challenge than the elimination of primary tumors.
525-534
Pop, Laurentiu M.
1f05dcbb-bb7c-46b5-b3c0-dffe8fbd14ae
Smallshaw, Joan E.
68c782c0-5ffb-4110-ad4e-7c0ba70c34e9
Tucker, Thomas F.
e315d8c0-808c-42e3-83ca-549006e61aa1
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Vitetta, Ellen S.
af8d0814-e2da-4b80-b80a-b96ffde6ef20
2005
Pop, Laurentiu M.
1f05dcbb-bb7c-46b5-b3c0-dffe8fbd14ae
Smallshaw, Joan E.
68c782c0-5ffb-4110-ad4e-7c0ba70c34e9
Tucker, Thomas F.
e315d8c0-808c-42e3-83ca-549006e61aa1
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Vitetta, Ellen S.
af8d0814-e2da-4b80-b80a-b96ffde6ef20
Pop, Laurentiu M., Smallshaw, Joan E., Tucker, Thomas F., Stevenson, Freda K. and Vitetta, Ellen S.
(2005)
Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma.
Journal of Immunotherapy, 28 (6), .
Abstract
Immunization of mice with the idiotype (Id) immunoglobulin from the murine B cell lymphoma, BCL1, before inoculating tumor cells can induce tumor dormancy. In this model, the tumor cells grow for a short period of time and then regress. The mice live for months or years with approximately 1 million tumor cells in their spleens. Some mice relapse due to decreases in the anti-Id antibody titers or the development of mutations in the residual tumor cells which render them refractory to negative signaling by the anti-Id antibody. In this study we determined whether we could eliminate the residual dormant cells by using a DNA vaccine against the Id or by immunomodulation of T-cell subsets in vivo. Our results demonstrate that dormancy can be maintained by further immunizations with either the BCL1 Id protein or DNA vaccine encoding its single-chain Fv fragment. We also found that a cytotoxic T-cell response was not induced by either in vivo administration of vaccine alone or by the vaccine plus interleukin-2. In addition the injection of anti-cytotoxic T-lymphocyte-associate antigen did not prolong dormancy. Finally, the in vivo administration of anti-CD25 to deplete regulatory T cells did not prolong dormancy. Dormancy in this model is dependent primarily upon anti-Id antibodies, our results suggest that other strategies to target residual dormant BCL1 cells are warranted. They also suggest that the elimination of dormant tumor may represent a greater challenge than the elimination of primary tumors.
This record has no associated files available for download.
More information
Published date: 2005
Identifiers
Local EPrints ID: 26531
URI: http://eprints.soton.ac.uk/id/eprint/26531
ISSN: 1524-9557
PURE UUID: cb716a78-a09e-432b-b377-3b97563dec1f
Catalogue record
Date deposited: 10 Apr 2006
Last modified: 23 Jul 2022 01:41
Export record
Contributors
Author:
Laurentiu M. Pop
Author:
Joan E. Smallshaw
Author:
Thomas F. Tucker
Author:
Ellen S. Vitetta
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics